28 April 2015
Protect valuable new season lambs
MILTON KEYNES, UK, April 28 2015 – Sheep producers are being urged to realise full value for the 2015 lamb crop by making sure valuable new season finishing lambs are vaccinated against pasteurellosis and the main clostridial diseases.
“The lambing season has been kind to many sheep producers this year thanks to the dry and warm spring weather, but with lamb prices tracking lower than they were this time last year losing any lambs to easily preventable diseases this summer makes no sense at all,” says MSD Animal Health (a division of Merck & Co., Inc., Kenilworth, NJ, USA.) technical manager John Atkinson MRCVS.
“Pasteurellosis continues to be a significant cause of death in unvaccinated lambs. Respiratory signs such as snotty noses may be seen, but sudden death is often the first sign of a problem for many sheep farmers. Whilst sudden death can have a variety of causes, many outbreaks are caused by pasteurellosis or clostridial disease. Pasteurella are a group of bacteria, with Mannheimia haemolytica and Bibersteinia trehalosi being the most important types to cause disease in sheep. Several deaths over a short period of time should certainly be investigated by your vet, but sporadic deaths – for example, one a week – should not be ignored either because they soon add up.”
He warns that the colostrum lambs receive from the ewe shortly after birth only gives them protection for a limited time against pasteurellosis and the clostridial diseases like pulpy kidney and lamb dysentery.
“It’s true that if ewes are vaccinated properly with HEPTAVAC®-P PLUS in the run up to lambing then the lambs will also gain immunity. This helps provide vital protection in the first few weeks of life, but this so called passive immunity only lasts for so long. Lambs that receive a good intake of colostrum only have antibodies against pasteurella for up to four weeks and clostridia for up to 12 weeks. This means that some early season lambs may already be unprotected and if we get a sudden change in the weather many will be at real risk from these prevalent disease threats unless they are vaccinated themselves.”
John Atkinson recommends vaccinating finishing lambs with OVIVAC®-P PLUS, pointing out that the cost of one severe outbreak of pasteurellosis equates to many years of vaccine use for the average flock.
“The vaccine can be used from three weeks of age and the primary course involves two vaccinations 4-6 weeks apart. Animals intended for breeding should be started on HEPTAVAC®-P PLUS instead because it provides optimal aid in the control of the predominant clostridial diseases in adult sheep.”
Ø Pasteurella and clostridial diseases are real threats in unvaccinated lambs
Ø Ewe colostrum gives lambs important disease protection, but only lasts for up to four weeks against pasteurella
Ø Vaccination with OVIVAC®-P PLUS will help protect finishing lambs from pasteurella and the main clostridial diseases until they are slaughtered.
Realise full value for 2015 lambs by making sure they vaccinated
against pasteuellosis and clostridial diseases.
Use medicines responsibly. For more information visit: www.noah.co.uk/responsible
HEPTAVAC-P PLUS and OVIVAC-P PLUS are only available from animal health product prescribers or veterinary surgeons from whom advice should be sought. HEPTAVAC-P PLUS contains antigens for the active immunisation of sheep against seven different clostridial species and the most important serotypes of Mannheimia (Pasteurella)trehalosi and Bibersteinia (Pasteurella) trehalosi. OVIVAC-P PLUS contains antigens from four clostridial species and the most important serotypes of Mannheimia (Pasteurella)trehalosi and Bibersteinia (Pasteurella) trehalosi. Legal categories POM-VPS. HEPTAVAC-P PLUS and OVIVAC-P PLUS are the property of Intervet International B.V. or affiliated companies or licensors and are protected by copyrights, trademark and other intellectual property laws. Copyright © 2014 Intervet International B.V. All rights reserved.
Further information is available from: MSD Animal Health, Walton Manor, Walton, Milton Keynes MK7 7AJ. Tel: 01908 685685 - email@example.com - www.msd-animal-health.co.uk
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).